PALO ALTO, Calif., Oct. 18, 2017 /PRNewswire/ -- AirXpanders, Inc. (ASX: AXP) (AirXpanders or Company), a medical device company focused on the design, manufacture, sale and distribution of the AeroForm® Tissue Expander System, announced today that its AeroForm System earned a Best of What's New award in the health category by Popular Science, the world's largest science and technology magazine.

Following a thorough review of thousands of new products and innovations, the AeroForm System is among the top 100 honorees that represent a significant step forward in their respective categories. All winners will be featured in the magazine's November/December special issue, available on newsstands and online now.

"For the past 40 years, breast tissue expansion has been a time consuming, sometimes painful process, often deterring women from undergoing breast reconstruction. However, with the advent of our breakthrough AeroForm technology, we have evolved this process by offering women a needle-free, patient-controlled approach to tissue expansion with an emphasis on comfort and convenience," said Scott Dodson, President & CEO, AirXpanders. "We're honored that Popular Science has recognized our engineering feat and commitment to providing breast cancer patients and their surgeons with best-in-class medical technology."

AeroForm offers a needle-free alternative for women who choose reconstructive surgery following a mastectomy. Inspired by a carbon dioxide bicycle pump canister, AeroForm is inserted underneath the chest muscle and activated by a handheld wireless controller that triggers a valve to release small amounts of carbon dioxide (CO2) up to three times a day, to gradually stretch the tissue to prepare for a breast implant. With the push of a button from the wireless controller, a preprogrammed amount of CO2 is delivered in seconds, allowing the patient to continue with her daily activities while preparing for reconstruction.

"The Best of What's New awards honor the innovations that shape the future," says Joe Brown, Editor-in-Chief, Popular Science. "From life-saving technology to incredible space engineering to gadgets that are just breathtakingly cool, this is the best of what's new."

AeroForm was granted de novo clearance by the U.S. Food and Drug Administration (FDA) in December 2016, subsequent U.S. market clearance in 2017, received CE mark in Europe in 2012 and Australian TGA certification in 2013. More than 1,000 women worldwide have benefitted from the AeroForm Tissue Expander System to date.

About Best of What's New

Each year, the editors of Popular Science review thousands of products in search of the top 100 tech innovations of the year—breakthrough products and technologies that represent a significant leap in their categories. The winners, the Best of What's New, are awarded inclusion in the much-anticipated November/December issue of Popular Science, the most widely read issue of the year since the debut of Best of What's New in 1988. Best of What's New awards are presented to 100 new products and technologies in 11 categories: Automotive, Aerospace, Engineering, Entertainment, Gadgets, General Innovation, Security, Software, Home, Health and Recreation.

About Popular Science

Founded in 1872, Popular Science is the world's largest science and technology magazine, with a circulation of 1.3 million and 6.8 million monthly readers. Each month, Popular Science reports on the intersection of science and everyday life, with an eye toward what's new and why it matters. Popular Science is published by Bonnier Active Media, a subsidiary of Bonnier Corporation.

About AirXpanders:

Founded in 2005, AirXpanders, Inc. (www.airxpanders.com) designs, manufactures and markets innovative medical devices to improve breast reconstruction. The company's AeroForm Tissue Expander System, is used in patients undergoing two-stage breast reconstruction following mastectomy.  Headquartered in Palo Alto, California, AirXpanders' vision is to be the global leader in reconstructive surgery products and to become the standard of care in two-stage breast reconstruction.  AirXpanders is a publically listed company on the Australian Securities Exchange under the symbol "AXP." AeroForm was granted U.S. FDA de novo marketing authorization in 2016, subsequent U.S. market clearance in 2017, first CE mark in Europe in 2012 and is currently licensed for sale in Australia. 

Forward-Looking Statements

This announcement contains or may contain forward-looking statements that are based on management's beliefs, assumptions and expectations and on information currently available to management.

All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. These include, without limitation, the benefits of AeroForm.

Management believes that these forward-looking statements are reasonable when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. AirXpanders may not actually achieve the plans, projections or expectations disclosed in forward-looking statements. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements. For additional information and considerations regarding the risks faced by AirXpanders that could cause actual results to differ materially, see its periodic reports filed with the Securities and Exchange Commission under the caption "Risk Factors," including its quarterly report on Form 10-Q for the quarter ended June 30, 2017. AirXpanders disclaims any obligation to update information contained in any forward-looking statement, except as required by law.

For more information, refer to the Company's website at www.airxpanders.com.

SOURCE AirXpanders, Inc.

Related Links

http://www.airxpanders.com